Division of Allergy Pulmonary and Critical Care Medicine

Matthew Semler, MD, MSc, and Cheryl Gatto, PhD, will lead the new Center for Learning Healthcare.
January 26, 2023

VUMC establishes novel Center for Learning Healthcare

Vanderbilt University Medical Center has established a first-of-its-kind Center for Learning Healthcare that will bring together clinicians, health system operations leaders and researchers to generate evidence in the course of health care delivery to continuously improve the quality, value and safety of health care offered to patients.

January 20, 2023

Vanderbilt mourns loss of ASAP co-founder Murray

John Joseph Murray V, MD, PhD, a co-founder of the Vanderbilt University Medical Center Asthma, Sinus and Allergy Program (ASAP), died on Jan. 6 at Vanderbilt University Hospital.

The clinical trial group includes, from left, Gordon Bernard, MD, Katherine Cahill, MD, Kevin Niswender, MD, PhD, Pingsheng Wu, PhD, and R. Stokes Peebles, MD.
November 10, 2022

Clinical trial at VUMC tests novel treatment for asthma

VUMC has begun enrolling patients with asthma in a clinical trial of a novel treatment: a medication approved to treat diabetes and obesity.

E. Wesley Ely, MD, MPH, speaks at last week’s Vanderbilt Translational Research Forum.
October 27, 2022

Translational Research Forum highlights range of studies

The 2022 Vanderbilt Translational Research Forum exemplified the range of studies conducted at Vanderbilt University Medical Center that are translating scientific discovery into clinical practice.

October 24, 2022

Vanderbilt study finds that the most common oxygen saturation targets for hospitalized patients appear equally safe and effective

A Vanderbilt study looked at the oxygen saturation target that results in optimal outcomes — number of days alive and free of mechanical ventilation — in 2,500 critically ill adults receiving mechanical ventilation.

October 20, 2022

New target for lung fibrosis

Blocking thromboxane-prostanoid receptor signaling protected animals from lung fibrosis in preclinical models, suggesting a new treatment for IPF — a chronic, progressive lung disorder that often kills within 3-5 years of diagnosis.